BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 32250729)

  • 21. Evaluation of the ETS-related gene mRNA in urine for the detection of prostate cancer.
    Rice KR; Chen Y; Ali A; Whitman EJ; Blase A; Ibrahim M; Elsamanoudi S; Brassell S; Furusato B; Stingle N; Sesterhenn IA; Petrovics G; Miick S; Rittenhouse H; Groskopf J; McLeod DG; Srivastava S
    Clin Cancer Res; 2010 Mar; 16(5):1572-6. PubMed ID: 20160063
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer.
    Hessels D; Smit FP; Verhaegh GW; Witjes JA; Cornel EB; Schalken JA
    Clin Cancer Res; 2007 Sep; 13(17):5103-8. PubMed ID: 17785564
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TMPRSS2-ERG fusion transcripts expression in patients referred for prostate biopsy: combining detection in urine and needle rinse material.
    Delongchamps NB; Younes P; Denjean L; Zerbib M; Bories PN
    World J Urol; 2015 Jun; 33(6):807-11. PubMed ID: 24997128
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A urine extracellular vesicle circRNA classifier for detection of high-grade prostate cancer in patients with prostate-specific antigen 2-10 ng/mL at initial biopsy.
    He YD; Tao W; He T; Wang BY; Tang XM; Zhang LM; Wu ZQ; Deng WM; Zhang LX; Shao CK; Zhou J; Rong LM; Gao X; Li LY
    Mol Cancer; 2021 Jul; 20(1):96. PubMed ID: 34301266
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic Significance of TMPRSS2-ERG Fusion Gene in Prostate Cancer.
    Kulda V; Topolcan O; Kucera R; Kripnerova M; Srbecka K; Hora M; Hes O; Klecka J; Babuska V; Rousarova M; Benson V; Pesta M
    Anticancer Res; 2016 Sep; 36(9):4787-93. PubMed ID: 27630329
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Correlation of urine TMPRSS2:ERG and PCA3 to ERG+ and total prostate cancer burden.
    Young A; Palanisamy N; Siddiqui J; Wood DP; Wei JT; Chinnaiyan AM; Kunju LP; Tomlins SA
    Am J Clin Pathol; 2012 Nov; 138(5):685-96. PubMed ID: 23086769
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prostate cancer gene 3 urine assay for prostate cancer in Japanese men undergoing prostate biopsy.
    Ochiai A; Okihara K; Kamoi K; Iwata T; Kawauchi A; Miki T; Fors Z
    Int J Urol; 2011 Mar; 18(3):200-5. PubMed ID: 21332814
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance.
    Nakanishi H; Groskopf J; Fritsche HA; Bhadkamkar V; Blase A; Kumar SV; Davis JW; Troncoso P; Rittenhouse H; Babaian RJ
    J Urol; 2008 May; 179(5):1804-9; discussion 1809-10. PubMed ID: 18353398
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PCA3: a molecular urine assay for predicting prostate biopsy outcome.
    Deras IL; Aubin SM; Blase A; Day JR; Koo S; Partin AW; Ellis WJ; Marks LS; Fradet Y; Rittenhouse H; Groskopf J
    J Urol; 2008 Apr; 179(4):1587-92. PubMed ID: 18295257
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy.
    McKiernan J; Donovan MJ; O'Neill V; Bentink S; Noerholm M; Belzer S; Skog J; Kattan MW; Partin A; Andriole G; Brown G; Wei JT; Thompson IM; Carroll P
    JAMA Oncol; 2016 Jul; 2(7):882-9. PubMed ID: 27032035
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TMPRSS2-ERG fusion transcripts in matched urine and needle rinse material after biopsy for the detection of prostate cancer.
    Bories PN; Younes P; Zerbib M; Denjean L; Popovici T; Cynober L; Delongchamps NB
    Clin Chem; 2013 Jan; 59(1):245-51. PubMed ID: 23045253
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multicenter Optimization and Validation of a 2-Gene mRNA Urine Test for Detection of Clinically Significant Prostate Cancer before Initial Prostate Biopsy.
    Haese A; Trooskens G; Steyaert S; Hessels D; Brawer M; Vlaeminck-Guillem V; Ruffion A; Tilki D; Schalken J; Groskopf J; Van Criekinge W
    J Urol; 2019 Aug; 202(2):256-263. PubMed ID: 31026217
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical utility of the prostate cancer gene 3 (PCA3) urine assay in Japanese men undergoing prostate biopsy.
    Ochiai A; Okihara K; Kamoi K; Oikawa T; Shimazui T; Murayama S; Tomita K; Umekawa T; Uemura H; Miki T
    BJU Int; 2013 May; 111(6):928-33. PubMed ID: 23331404
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Performance of PCA3 and TMPRSS2:ERG urinary biomarkers in prediction of biopsy outcome in the Canary Prostate Active Surveillance Study (PASS).
    Newcomb LF; Zheng Y; Faino AV; Bianchi-Frias D; Cooperberg MR; Brown MD; Brooks JD; Dash A; Fabrizio MD; Gleave ME; Liss M; Morgan TM; Thompson IM; Wagner AA; Carroll PR; Nelson PS; Lin DW
    Prostate Cancer Prostatic Dis; 2019 Sep; 22(3):438-445. PubMed ID: 30664734
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prostate cancer gene 3 score predicts prostate biopsy outcome in men receiving dutasteride for prevention of prostate cancer: results from the REDUCE trial.
    Aubin SM; Reid J; Sarno MJ; Blase A; Aussie J; Rittenhouse H; Rittmaster RS; Andriole GL; Groskopf J
    Urology; 2011 Aug; 78(2):380-5. PubMed ID: 21820580
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expressed prostatic secretion biomarkers improve stratification of NCCN active surveillance candidates: performance of secretion capacity and TMPRSS2:ERG models.
    Whelan C; Kawachi M; Smith DD; Linehan J; Babilonia G; Mejia R; Wilson T; Smith SS
    J Urol; 2014 Jan; 191(1):220-6. PubMed ID: 23669563
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2-10ng/ml at Initial Biopsy.
    McKiernan J; Donovan MJ; Margolis E; Partin A; Carter B; Brown G; Torkler P; Noerholm M; Skog J; Shore N; Andriole G; Thompson I; Carroll P
    Eur Urol; 2018 Dec; 74(6):731-738. PubMed ID: 30237023
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications.
    Mosquera JM; Perner S; Genega EM; Sanda M; Hofer MD; Mertz KD; Paris PL; Simko J; Bismar TA; Ayala G; Shah RB; Loda M; Rubin MA
    Clin Cancer Res; 2008 Jun; 14(11):3380-5. PubMed ID: 18519767
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer.
    Laxman B; Tomlins SA; Mehra R; Morris DS; Wang L; Helgeson BE; Shah RB; Rubin MA; Wei JT; Chinnaiyan AM
    Neoplasia; 2006 Oct; 8(10):885-8. PubMed ID: 17059688
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume.
    Whitman EJ; Groskopf J; Ali A; Chen Y; Blase A; Furusato B; Petrovics G; Ibrahim M; Elsamanoudi S; Cullen J; Sesterhenn IA; Brassell S; Rittenhouse H; Srivastava S; McLeod DG
    J Urol; 2008 Nov; 180(5):1975-8; discussion 1978-9. PubMed ID: 18801539
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.